Terrance Mcguire Sells 75,776 Shares of Invivyd, Inc. (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 75,776 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.45, for a total value of $34,099.20. Following the completion of the transaction, the director now directly owns 3,492,498 shares in the company, valued at $1,571,624.10. This trade represents a 2.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Terrance Mcguire also recently made the following trade(s):

• On Thursday, December 26th, Terrance Mcguire sold 83,817 shares of Invivyd stock. The shares were sold at an average price of $0.54, for a total transaction of $45,261.18.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The stock was sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Performance

Shares of Invivyd stock opened at $0.51 on Friday. The company has a market capitalization of $61.00 million, a PE ratio of -0.26 and a beta of 0.53. The company has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $0.97. Invivyd, Inc. has a one year low of $0.40 and a one year high of $5.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Proficio Capital Partners LLC purchased a new stake in Invivyd during the third quarter valued at approximately $27,000. XTX Topco Ltd increased its position in shares of Invivyd by 68.1% during the second quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after purchasing an additional 15,376 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock valued at $42,000 after purchasing an additional 25,201 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new stake in shares of Invivyd in the 2nd quarter worth $86,000. Finally, Rhumbline Advisers grew its stake in Invivyd by 4,434.1% during the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after buying an additional 82,164 shares during the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on IVVD shares. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Morgan Stanley reduced their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. HC Wainwright lowered their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Invivyd in a report on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.